163 related articles for article (PubMed ID: 37779396)
21. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
Rosenberg JD; Burian C; Waalen J; Saven A
Blood; 2014 Jan; 123(2):177-83. PubMed ID: 24192579
[TBL] [Abstract][Full Text] [Related]
22. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
23. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
Rai KR
Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
Hermel DJ; Cheng B; Bhangoo MS; Burian C; Waalen J; Saven A
Ann Hematol; 2022 May; 101(5):1089-1096. PubMed ID: 35218397
[TBL] [Abstract][Full Text] [Related]
25. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
26. [Successful induction and complete improvement of myelofibrosis and erythema nosodum with cladribine in a case of hairy cell leukemia].
Araki H; Matsunaga T; Murase K; Kuroda H; Kuribayashi K; Terui T; Niitsu Y
Gan To Kagaku Ryoho; 2004 Jun; 31(6):965-9. PubMed ID: 15222122
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
28. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
Buckstein R; Patel H; Chesney A; Reis M; Imrie K
Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
[TBL] [Abstract][Full Text] [Related]
29. Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options.
Polliack A
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():41-51. PubMed ID: 9570679
[TBL] [Abstract][Full Text] [Related]
30. Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature.
Al-Fiar F; Meharchand J; Curtis J; Lipton JH
Leuk Res; 1999 Aug; 23(8):719-21. PubMed ID: 10456669
[TBL] [Abstract][Full Text] [Related]
31. Advances in the treatment of hairy-cell leukaemia.
Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
[TBL] [Abstract][Full Text] [Related]
33. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
34. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
35. [Hairy cell leukemia therapy by cladribine].
Ogura M
Nihon Rinsho; 2004 Jul; 62(7):1337-42. PubMed ID: 15283153
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
37. Cladribine in the treatment of hairy-cell leukaemia.
Goodman GR; Beutler E; Saven A
Best Pract Res Clin Haematol; 2003 Mar; 16(1):101-16. PubMed ID: 12670469
[TBL] [Abstract][Full Text] [Related]
38. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
39. Treatment of hairy cell leukemia: long-term results in a developing country.
Ruiz-Delgado GJ; Tarín-Arzaga LC; Alarcón-Urdaneta C; Calderón-García J; Gómez-Almaguer D; Ruiz-Argüelles GJ
Hematology; 2012 May; 17(3):140-3. PubMed ID: 22664112
[TBL] [Abstract][Full Text] [Related]
40. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
